DTDeena A. Tajfirouz

Deena A. Tajfirouz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Deena A. Tajfirouz has a total of 126 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Application of Optic Neuritis Diagnostic Criteria in Autoimmune Paraneoplastic CRMP5 Optic Neuropathy and Development of the “CRMP” Score

    by Alessandro Dinoto, Devon A. Cohen, Laura Cacciaguerra, Nanthaya Tisavipat, Stephanie B. Syc-Mazurek, Vanda A. Lennon, M. Tariq Bhatti, Deena A. Tajfirouz, Kevin D. Chodnicki, Sean J. Pittock, et al.

    Collapsin response-mediator protein 5 (CRMP5)-IgG is an acknowledged biomarker in the International Consortium on Optic Neuritis (ICON) diagnostic criteria for optic neuritis (ON), but these criteria have not been validated in CRMP5-IgG+ON. We evaluated the ICON and Acute Optic Neuritis Network (ACON) criteria for CRMP5-IgG+ON, using patients with late-onset (age ≥50 years) aquaporin-4-IgG-positive (AQP4-IgG+)-ON or myelin-oligodendrocyte glycoprotein antibody (MOG-IgG+)-ON for comparison. We developed the "CRMP score," based on typical CRMP5-IgG+ON clinical features, to guide CRMP5 antibody testing in ON. The study included 17 patients with CRMP5-IgG+, 11 with AQP4-IgG+ON, and 13 with MOG-IgG+ON. Application of ICON criteria yielded no "definite ON" and 1 "probable ON" diagnosis among the 17 CRMP5-IgG+ cases, but definite ON diagnoses for 6 of 11 AQP4-IgG+ (55%, p = 0.003) and 7 of 13 MOG-IgG+ cases (54%, p = 0.001). ACON criteria yielded definite ON diagnoses for 2 (12%) CRMP5-IgG+ON, 10 (91%) of the AQP4-IgG+ON, and 13 (100%) of the MOG-IgG+ON (p < 0.001). A CRMP score ≥1 identified CRMP5-IgG+ON with a sensitivity of 88.2% and a specificity of 87.5%. ICON and ACON criteria for ON diagnosis identified only a minority of CRMP5-IgG+ON cases; thus, we developed the "CRMP" score to aid their identification in clinical practice.

  • Amaurosis Fugax Dolorosa

    by Andreu Vilaseca, Stephanie B. Syc-Mazurek, Nisa Vorasoot, Deena A. Tajfirouz, Eric Eggenberger, Kevin D. Chodnicki, Sean J. Pittock, John J. Chen, Eoin P. Flanagan

  • Outcomes of Maintenance Immunotherapy in a Cohort of Patients With Susac Syndrome

    by Negar Moheb, Deena A. Tajfirouz, Kevin D. Chodnicki, Andrew McKeon, Natthapon Rattanathamsakul, Abdul-Rahman Salman, Leigh A. Rettenmaier, Aditi Varma-Doyle, Bart K. Chwalisz, John J. Chen

    Susac syndrome (SuS) is a rare autoimmune disorder characterized by the classic clinical triad of encephalopathy, sensorineural hearing loss, and branch retinal artery occlusion (BRAO). Maintenance immunotherapy is important in most cases to prevent new attacks that can cause significant disability. However, owing to the rarity of SuS, there are few large studies evaluating the efficacy of immunotherapies in SuS. In this large case series, we evaluated the association of utilized immunotherapies and relapse rates in the management of SuS from a large multicenter cohort. Retrospective data analysis of 54 patients with definite or probable SuS diagnoses who were evaluated and managed at 2 academic medical centers in the United States. The percentage with relapse and annualized relapse rate (ARR) were calculated for each immunotherapy. The median age at diagnosis of SuS was 36.5 years (interquartile range 30-46 years), and 61% were female. On maintenance immunotherapy, the relapse rate and median ARR were as follows: mycophenolate mofetil 40% (12 of 30 with a median duration of 1.08 years; ARR 0), low or intermediate dose IV immunoglobulin (IVIG) 42.3% (11 of 26 with a median duration of 0.75 years; ARR 0.1), high dose IVIG 11.7% (2 of 17 with a median duration of 0.58 years; ARR 0), cyclophosphamide 36.3% (8 of 22 with a median duration 0.5 years; ARR 0), rituximab 38% (8 of 21 with a median duration of 1.58 years; ARR 0), azathioprine 60% (3 of 5 with a median duration of 1.33 years; ARR 0.1), methotrexate 66.6% (2 of 3 with a median duration of 5.5 years, ARR 0.1), infliximab 0% (0 of 1 with duration of 0.66 years; ARR 0), maintenance plasma exchange 0% (0 of 1 with duration of 1.25 years; ARR 0), and tocilizumab 0% (0 of 1 with duration of 0.91; ARR 0). Our relatively large cohort of patients with SuS shows a variety of maintenance immunotherapies are used with varying response rates. Among our patients, a number of refractory cases required aggressive and combination of immunotherapies.


  • Open Access

    Amaurosis Fugax Dolorosa

    by Andreu Vilaseca, Stephanie B. Syc-Mazurek, Nisa Vorasoot, Deena A. Tajfirouz, Eric Eggenberger, Kevin D. Chodnicki, Sean J. Pittock, John J. Chen, Eoin P. Flanagan

    Amaurosis fugax (AF) is typically vascular but can rarely be associated with optic neuritis (ON). We describe AF preceding myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) ON. We retrospectively reviewed our MOGAD cohort (July 2024-April 2024). Inclusion criteria were (1) AF-defined as transient visual loss <24 hours without retinal ischemic lesions-before first ON and (2) fulfilled international MOGAD 2023 diagnostic criteria. Demographics, symptoms/signs, MRI, and optical coherence tomography (OCT) data were collected. Descriptive statistics summarized the findings. In total, 8 of 350 (2.3%) MOGAD patients with ON experienced AF. Most patients (7/8, 87.5%) were women, and all reported periocular pain. Transient visual episodes were typically brief (median, 15 minutes; range, 1-300 minutes) and usually less than 1 hour (6/8, 75.0%). Amaurosis fugax affected the right (n = 4), left (n = 3), or both (n = 1) eyes. Within 1 week, 7 developed ON. MRI showed optic nerve enhancement in involved eye in 8 of 8 (100%). OCT completed in 1 patient at the time of AF showed increased peripapillary retinal nerve fiber layer thickness. No alternative diagnoses emerged during follow-up. Painful AF is a previously unrecognized and specific prodrome of MOGAD-associated ON; identifying this rare presentation may enable earlier diagnosis and treatment.


  • Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

    by Smathorn Thakolwiboon, Vyanka Redenbaugh, Bo Chen, Sage Hewitt, Shailee Shah, Itay Lotan, Michael Levy, Mirasol Forcadela, Saif Huda, Julie Pique, et al.

    Data on the plasma exchange (PLEX) in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are limited. Herein, we evaluate outcomes after PLEX in MOGAD. This international multicenter retrospective cohort study included patients from 18 tertiary care centers in 6 countries. Inclusion criteria included fulfillment of the 2023 International MOGAD panel criteria, receipt of at least 3 sessions of PLEX, and follow-up of ≥3 months after PLEX. Patients with coexisting neuroinflammatory disorders were excluded. We assessed the frequency of complete recovery (CR), clinically significant improvement (CSI), visual acuity (VA), and Expanded Disability Status Scale (EDSS). Logistic regression analyses were performed to identify predictors of CR and CSI. Of 234 patients, 135 (58%) were female. The median (interquartile range [IQR]) age at attack was 34 (IQR 22-49) years, and 42 (17%) were children. In 165 of 243 (68%), the attack treated with PLEX was the first attack. Attack phenotypes included 161 optic neuritis (235 eyes), 77 myelitis, 24 acute disseminated encephalomyelitis, 15 brainstem/cerebellar, 3 cerebral-cortical encephalitis attack, and 1 cerebral polyfocal deficit-36 with >1 core phenotypes. A total of 239 (99%) attacks were also treated with corticosteroids and 32 (13%) with IV immunoglobulins. VA in optic neuritis improved from 20/400 (20/70-hand motion) to 20/20 (20/20-20/30), p < 0.001, and EDSS decreased from a median of 4.0 (3.0-6.5) to 1.0 (0.0-2.5), p < 0.001. Of 229 attacks without subsequent attacks within 3 months, 100 (44%) achieved CR and 213 (93%) CSI. The probability of CR was decreased with advanced age (adjusted odd ratio [95% CI] 0.97 [0.96-0.99] per year), higher EDSS worsening from baseline (0.66 [0.54-0.81] per 0.5 increment) and delayed PLEX (0.98 [0.96-0.99] per day). Advanced age (0.97 [0.96-0.99] per year) and delayed PLEX (0.95 [0.94-0.96] per day) decreased the probability of CSI. We observed favorable outcomes after PLEX in MOGAD attacks. However, advanced age and delayed initiation of PLEX were associated with a reduced probability of improvement. The absence of a control group limits our ability to differentiate PLEX effects from spontaneous recovery, prior corticosteroid response, or long-term immunotherapy. Future prospective studies are needed to assess the impact of PLEX on improvement. This study provides Class IV evidence that PLEX is associated with favorable clinical outcomes in patients with MOGAD.


  • Unveiling Misdiagnosis: Rethinking Seronegative NMOSD

    by Mary V. Lang, Grant M. Welk, Deena A. Tajfirouz, Kevin D. Chodnicki, Sean J. Pittock, Eoin P. Flanagan, John J. Chen

    Seronegative neuromyelitis optica spectrum disorder (NMOSD) is a diagnostic challenge. This study aimed to characterize misapplication of the 2015 international criteria for seronegative NMOSD. We reviewed 35 consecutive seronegative NMOSD referrals to a tertiary center. Two (6%) met formal criteria, and 2 (6%) were clinically suspected of NMOSD without fulfilling radiologic supportive criteria. Alternative diagnoses were common including multiple sclerosis (37%), optic neuritis (14%), functional neurologic disorder (11%), and other (38%). Immunosuppression with rituximab was used in 3 of 4 patients with functional neurologic disorder. Misapplication of the 2015 criteria is common, and alternative explanations in seronegative NMOSD patients should be strongly considered.


  • MRI characteristics during attack and remission distinguish patients with MOG antibody-associated disease from multiple sclerosis

    by Stephanie B Syc-Mazurek, Laura Cacciaguerra, Deena A Tajfirouz, Vyanka Redenbaugh, Karl N Krecke, Smathorn Thakolwiboon, Alessandro Dinoto, Ajay Madhavan, Jan-Mendelt Tillema, A Sebastian Lopez-Chiriboga, et al.

    Background Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and multiple sclerosis (MS) have both overlapping and distinct MRI lesion features, which vary with imaging timing. This study identified distinguishing MRI characteristics using paired MRIs at clinical attack and remission. Methods We retrospectively identified Mayo Clinic patients with MOGAD and MS that: (1) fulfilled respective diagnostic criteria; (2) had paired attack (≤30 days) and remission MRI scans (≥12 months) without interval attacks. MRIs were compared between groups for key features. Results We included 43 patients with MOGAD (median age 31 years (range, 3–67); 63% female) and 49 patients with MS (median age 39 years (range, 17–65); 65% female). Resolution of at least one T2-lesion differentiated MOGAD from MS (sensitivity, (95% CI 77% to 100%), specificity, (95% CI 86% to 99%); Youden’s index (YI)=0.90). Resolution of at least two T2-lesions indicated MOGAD (sensitivity 62% (95% CI 41% to 79%); specificity, 100% (95% CI 94% to 100%); YI=0.62). MOGAD patients were more likely to have normal MRI scans at follow-up compared with MS (brain 14/44 (32%) vs 0/60 (0%), pConclusion Paired MRI at attack and remission revealed distinctive characteristics of MOGAD and MS, with greater diagnostic value at remission driven by the discriminating power of T2-lesion resolution. In MOGAD patients with initial parenchymal involvement, a 1-year follow-up MRI may aid diagnosis and serve as a new baseline.


  • Clinical Features and Factors Associated With Outcome in Late Adult-Onset Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

    by Alessandro Dinoto, Laura Cacciaguerra, Nisa Vorasoot, Vyanka Redenbaugh, Sebastian A. Lopez-Chiriboga, Cristina Valencia-Sanchez, Kai Guo, Smathorn Thakolwiboon, Susan E. Horsman, Stephanie B. Syc-Mazurek, et al.

    Data regarding late adult-onset myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are scant. This study sought to assess the frequency, characteristics, and outcome of late adult-onset MOGAD and identify differences from early adult-onset MOGAD. This retrospective, observational study included Mayo Clinic patients with MOGAD per 2023 diagnostic criteria and with onset age 50 years or older. Clinical, laboratory, radiologic, treatment, and outcome data were collected and compared between patients aged 50-59 years and those aged 60 years or older. Finally, the characteristics and outcome of patients with late adult-onset MOGAD (aged 50 or older) were compared with a reference group of patients with early adult-onset (aged 18-49) MOGAD (n = 141). There were 107 patients with late adult-onset MOGAD included, representing 25% of the MOGAD cohort (n = 436). The median age at onset was 59 years (range: 50-88), and 71 (66%) were female. Medical comorbidities were noted in 86 of 105 (83%). Optic neuritis was the most frequent onset attack (77/107, 72%), and the median Expanded Disability Status Scale (EDSS) score at nadir was 3 (range: 1-9). In 32 of 107 (30%), a potential trigger was noted, mostly infections. In 32 patients (30%), an alternative diagnosis was considered before MOGAD identification, most commonly giant cell arteritis (n = 15 [11 undergoing temporal artery biopsy]). By a median follow-up duration of 22 months (range: 0-306), 50 patients (47%) had a relapsing course, and preventive treatment was administered in 53 (50%). Medication side effects were common (41/107, 38%). No differences were observed in patients with MOGAD aged 50-59 years vs 60 years or older. Lastly, late adult-onset patients had more optic nerve involvement (p = 0.015; OR: 1.9; 95% CI 1.1-3.3), brainstem/cerebellar involvement (p = 0.008; OR: 3.4; 95% CI 1.1-3.3), and cognitive decline (p = 0.01; OR: 5.3; 95% CI 1.4-19.4) and less frequent myelitis (p < 0.001; OR: 0.4; 95% CI 0.2-0.7) vs those with early adult-onset MOGAD, but EDSS scores and frequency of a relapsing course were similar. Late adult-onset MOGAD accounts for one-quarter of patients with MOGAD. Optic neuritis is the dominant phenotype in this age group with MOGAD and is under-recognized and frequently misdiagnosed. Outcomes in late adult-onset MOGAD are similar to those in early adult-onset disease.


  • Assessment of increased opening pressure in patients with multiple sclerosis and aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder

    by Sydney Roston, Melanie H Quick, Nanthaya Tisavipat, Natthapon Rattanathamsakul, Laura Cacciaguerra, Deena A Tajfirouz, Kevin D Chodnicki, Jan-Mendelt Tillema, Sean J Pittock, Eoin P Flanagan, et al.

    Increased intracranial pressure (ICP) is increasingly recognized in myelin oligodendrocyte glycoprotein antibody-associated disease but has not been systematically explored in other demyelinating conditions. This cross-sectional study examines the features of raised ICP in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS). Lumbar puncture opening pressure (OP) done within 30 days of an attack was identified in 41 NMOSD patients and 37 MS patients. Raised OP was present in 7 (17.1%) NMOSD patients and 4 (10.8%) MS patients who were largely asymptomatic, partially explained by obesity, and did not require ICP lowering medications beyond acute treatment with corticosteroids.


  • Open Access

    Longitudinal Evolution of Posterior Cortical Atrophy

    by Dror Shir, Noah Lee, Stuart J. McCarter, Vijay K. Ramanan, Hugo Botha, David S. Knopman, Ronald C. Petersen, Bradley F. Boeve, Gregory Scott Day, Neill R. Graff-Radford, et al.

    Although several large studies have evaluated individuals with posterior cortical atrophy (PCA) cross-sectionally, its longitudinal progression remains poorly characterized. The objectives of this study were to determine the longitudinal trajectory of PCA, encompassing the temporal aspects of diagnosis, the spectrum of clinical manifestations, and patient outcomes. This retrospective study included participants evaluated and diagnosed with PCA at the Mayo Clinic, between 1995 and 2023. Clinical data (demographics, neurologic evaluations, and cognitive tests at initial presentation and late stage) were extracted from medical records. Initial clinical diagnoses during previous medical evaluations, including ophthalmologic assessments after onset of neurologic symptoms, were documented. Participants were retrospectively classified as PCA-pure if they solely met PCA criteria or as PCA-plus if they exhibited complex phenotypes also meeting criteria for other neurodegenerative syndromes. CSF analyses and neuropathology findings were documented. The cohort of 558 participants (65% female) had a mean age at symptom onset of 61 ± 8 years, with 68% meeting early-onset criteria (younger than 65 years). The mean duration from symptom onset to diagnosis was 3.6 ± 2.5 years. Ophthalmologic/optometric evaluations (49%) and completion of ophthalmologic procedures (16%) were common before PCA diagnosis. Psychiatric diagnoses were made in 23% of participants before PCA diagnosis, particularly among younger women. Common initial symptoms included misplacement of items, difficulties with reading and driving, and concerns pertaining to basic visual processing. Notable signs were constructional apraxia, dyscalculia, simultanagnosia, and space perception deficits. CSF biomarkers were consistent with Alzheimer disease in 139 of 158 individuals (88%). Superimposed features of non-PCA clinical syndromes were observed in a quarter of the participants at presentation, with frequency of PCA-plus cases increasing longitudinally. Longitudinal analysis of Short Test of Mental Status scores predicted an initial rapid decline in cognitive function, with the rate of decline gradually slowing over 0-10 years (time coefficient [SE] = -4.20 [0.29], p < 0.001). This study highlights the protracted time from symptom onset and frequent misdiagnoses/misattribution of symptoms in PCA. Ophthalmologic evaluations often preceded neurologic assessments. Psychiatric diagnoses were more frequent among younger women. These observations highlight the need to improve diagnostic processes and earlier recognition of PCA, which may enhance the effectiveness of emerging disease-modifying therapies.